Eloctate FDA Approval History
Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.
Development Timeline for Eloctate
|Jun 6, 2014||FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.